Wang YM - Search Results

1

Population pharmacokinetic-pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure.

Vu T, Ma P, Xiao JJ, Wang YM, Malik FI, Chow AT. Vu T, et al. Among authors: wang ym. J Clin Pharmacol. 2015 Nov;55(11):1236-47. doi: 10.1002/jcph.538. Epub 2015 Jul 14. J Clin Pharmacol. 2015. PMID: 25951506 Clinical Trial.

2

Development of biosimilars--pharmacokinetic and pharmacodynamic considerations.

Wang YM, Chow AT. Wang YM, et al. J Biopharm Stat. 2010 Jan;20(1):46-61. doi: 10.1080/10543400903280357. J Biopharm Stat. 2010. PMID: 20077248 Review.

3

Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects.

Wang YM, Krzyzanski W, Doshi S, Xiao JJ, Pérez-Ruixo JJ, Chow AT. Wang YM, et al. AAPS J. 2010 Dec;12(4):729-40. doi: 10.1208/s12248-010-9234-9. Epub 2010 Oct 21. AAPS J. 2010. PMID: 20963535 Free PMC article.

4

Romiplostim dose-response in patients with myelodysplastic syndromes.

Perez Ruixo JJ, Doshi S, Wang YM, Mould DR. Perez Ruixo JJ, et al. Among authors: wang ym. Br J Clin Pharmacol. 2013 Jun;75(6):1445-54. doi: 10.1111/bcp.12041. Br J Clin Pharmacol. 2013. PMID: 23171070 Free PMC article.

5

Evaluating and Reporting the Immunogenicity Impacts for Biological Products--a Clinical Pharmacology Perspective.

Wang YM, Wang J, Hon YY, Zhou L, Fang L, Ahn HY. Wang YM, et al. Among authors: wang j. AAPS J. 2016 Mar;18(2):395-403. doi: 10.1208/s12248-015-9857-y. Epub 2015 Dec 31. AAPS J. 2016. PMID: 26721560 Free PMC article. Review.

6

Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies.

Putnam WS, Prabhu S, Zheng Y, Subramanyam M, Wang YM. Putnam WS, et al. Among authors: wang ym. Trends Biotechnol. 2010 Oct;28(10):509-16. doi: 10.1016/j.tibtech.2010.07.001. Epub 2010 Aug 4. Trends Biotechnol. 2010. PMID: 20691488 Review.

7

Biological products for the treatment of psoriasis: therapeutic targets, pharmacodynamics and disease-drug-drug interaction implications.

Wang J, Wang YM, Ahn HY. Wang J, et al. Among authors: wang ym. AAPS J. 2014 Sep;16(5):938-47. doi: 10.1208/s12248-014-9637-0. Epub 2014 Jul 4. AAPS J. 2014. PMID: 24993574 Free PMC article. Review.

8

Experimental and statistical approaches in method cross-validation to support pharmacokinetic decisions.

Thway TM, Ma M, Lee J, Sloey B, Yu S, Wang YM, Desilva B, Graves T. Thway TM, et al. Among authors: wang ym. J Pharm Biomed Anal. 2009 Apr 5;49(3):613-8. doi: 10.1016/j.jpba.2008.12.008. Epub 2008 Dec 13. J Pharm Biomed Anal. 2009. PMID: 19150189

9

Immunogenicity and PK/PD evaluation in biotherapeutic drug development: scientific considerations for bioanalytical methods and data analysis.

Wang YM, Jawa V, Ma M. Wang YM, et al. Bioanalysis. 2014 Jan;6(1):79-87. doi: 10.4155/bio.13.302. Bioanalysis. 2014. PMID: 24341496 Review.

10

A survey of applications of biological products for drug interference of immunogenicity assays.

Wang YM, Fang L, Zhou L, Wang J, Ahn HY. Wang YM, et al. Among authors: wang j. Pharm Res. 2012 Dec;29(12):3384-92. doi: 10.1007/s11095-012-0833-2. Epub 2012 Aug 18. Pharm Res. 2012. PMID: 22903525

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,711 results

Search Page

Filters